Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Sowunmi, Akintunde ^a   Akano, Kazeem ^a   Ayede, Adejumoke I ^a   Ntadom, Godwin ^b   Fatunmbi, Bayo ^c   Aderoyeje, Temitope ^d   Adewoye, Elsie O ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b Federal Ministry of Health   (Nigeria)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Artemisinin based combination treatments; Children; Fall in haematocrit; Malaria; Nigeria

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DRUG ACTIVITY; DRUG HALF LIFE; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; MALARIA, FALCIPARUM; MULTIMODALITY CANCER THERAPY; PARASITOLOGY; PRESCHOOL CHILD;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; AMODIAQUINE; ANEMIA; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HEMATOCRIT; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84945243590     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1219-y     Document Type: Article

References (46)

1. World Health Organization. The use of Antimalarial drugs. Report of a WHO informal consultation. Document WHO/CDS/RBM/2001.33. Geneva: WHO; 2001.
2. World Health Organization. Antimalarial drugs combination therapy. Report of a WHO technical consultation. Document WHO/CDS/RBM/2001.35. Geneva: WHO; 2001.
3. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330-4.
4. Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg. 2007;77 Suppl 6:193-7.
5. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artemisinin versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717-25.
6. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647-57.
7. World Health Organization. Guidelines for the Treatment of Malaria. 2nd ed. Geneva, Switzerland: World Health Organization; 2010.
8. Zoller T, Junghanss T, Kapaun A, Gjørup I, Richter J, Hugo-Persson M, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerging Inf Dis. 2011;17:771-7.
9. Kreeftmeijer-Vetger AR, Genderen PJ, Visser LG, Bierman WFW, Clerinx J, van Veldehuizen CKW, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in Netherlands and Belgium. Malaria J. 2012;11:102-12.
10. World Health Organization. WHO Information Note on Delayed Haemolytic Anaemia Following Treatment with Artesunate. Geneva, Switzerland: WHO; 2013.
11. Medicine for Malaria Venture: Experts Group Meeting on Delayed Haemolytic Anaemia Following Treatment with Injectable Artesunate. Vienna, Austria, 2013. (http:/ www.mmv.org/newsroom/events/expert-group-meeting-safety-profile-injectable-artesunate ).
12. Price RC, Simpson JA, Nosten F, Luxemberger C, Hkirjaroen L, ter Kuile F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg. 2001;65:614-22.
13. Sowunmi A, Gbotosho GO, Happi CT, Fateye BA. Factors contributing to anaemia after uncomplicated Plasmodium falciparum malaria in children. Acta Trop. 2010;133:155-61.
14. Ouedraogo HZ, Zeba A, Dramaix-Wilmet M, Donnen P. Moderate to severe anaemia due to afebrile Plasmodium falciparum infections in children aged 6-23 months from rural district of Kongoussi, Burkina Faso. J Trop Pediatr. 2008;54:395-400.
15. Sumbele IUN, Samje M, Nkuo-Akenji T. A longitudinal study on anaemia in children with Plasmodium falciparum infection in the Mount Cameroon region: prevalence, risk factors and perceptions by caregivers. BMC Infect Dis. 2013;13:123.
16. Biemba G, Gorduek VR, Thuma P, Weiss G. Markers of inflammation in children with severe malaria. Trop Med Int Health. 2000;5:256-62.
17. Helleberg M, Goka BQ, Akanmori BD, Obeng-Adjei G, Rodriques O, Kurtzhals JAL. Bone marrow suppression and severe anaemia associated with persistent Plasmodium falciparum infection in African children with microscopically undetectable parasitaemia. Malaria J. 2005;4:56.
18. Awah NW, Troye-Blomberg M, Berzins K, Gysin J. Mechanisms of malarial anaemia: potential involvement of Plasmodium falciparum low molecular weight rhoptry-associated proteins. Acta Trop. 2009;112:299-302.
19. Premji Z, Umeh RE, Uwusu-Agyei S, Fabian E, Ezedinachi EU, Oguche S, et al. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One. 2009;4, e6682.
20. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Michael SO, et al. Therapeutic efficacy and effect of artemether-lumefantrine and artesunate-amodiaquine cofomulated or copackaged on malaria-associated anemia in children in uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg. 2011;84:813-9.
21. Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925-35.
22. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Adewoye EO. A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated malaria in children: Comparison of therapeutic efficacy with standard dose regimen of artesunate-lumefantrine. Am J Therap. 2011;19, e122.
23. Sowunmi A, Akinrinola AA, Gbotosho GO, Okuboyejo TM, Happi CT. A simple dose regimen of artesunate and amodiaquine based on arm span- or age range for childhood falciparum malaria: A preliminary evaluation. J Trop Ped. 2012;58:263-8.
24. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94 Suppl 1:1-90.
25. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT. Effects of amodiaquine, artesunate, and artesunate-amodiaquine of Plasmodium falciparum malaria-associated anaemia in children. Acta Trop. 2009;109:55-60.
26. Sowunmi A, Gbotosho GO, Happi CT, Folarin O, Okuboyejo T, Michael O, et al. Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anaemia after treatment. Am J Therap. 2011;18:1190-7.
27. Rowland M, Tozer TN. Clinical pharmacokinetics: concept and application. Philadelphia: Philadelphia PA Lea and Ferbiger; 1980. p. 288-91.
28. Bain BJ, Bates I. Basic haematological techniques. In: Lewis SM, Bain BJ, Bates I, editors. Practical Haematology. 9th ed. Edinburgh: Churchill Living stone; 2001. p. 19-46.
29. Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-compatible Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention; 1994.
30. SPSS for Windows Release 20.0 (standard version). SPSS Inc., Chicago IL; 2011.
31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;i:307-10.
32. Sowunmi A, Gbotosho GO, Happi C, Okuboyejo T, Folarin O, Balogun S, et al. Therapeutic efficacy and effects of artesunate-mefloquine and mefloquine alone on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg. 2009;81:979-86.
33. Fleming AF, Storey J, Molineaux L, Iroko EA, Attai ED. Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationship between sickle cell trait, malaria and survival. Ann Trop Med Parasitol. 1979;73:161-72.
34. Mockenhaupt FP, Falusi AG, May J, Ademowo OG, Olumese PE, Meyer CG, et al. The contribution of aα-thalassaemia to anaemia in Nigeria population exposed to intense malaria transmission. Trop Med Int Health. 1999;4:302-7.
35. Bienzle U. Glucose-6-phosphate dehydrogenase deficiency. Part 1: Tropical Africa. Clin Haematol. 1981;10:785-99.
36. Adewunmi CO, Gebremedhin G, Becker W, Olorunmola FO, Dorfler G, Adewunmi TA. Schistosomiasis and intestinal parasites in rural villages in southwest Nigeria: an indication for expanded programme on drug distribution and integrated control programme in Nigeria. Trop Med Parasitol. 1993;44:177-80.
37. White NJ, Ho M. The pathopysiology of malaria. In: Baker JR, Muller R, editors. Adv in Parasitol 1992. New York: Academic; 1992. p. 84-175.
38. Jakeman GN, Saul A, Hogarith WL, Collins WE. Anaemia of acute malaria infection in non-immune patients primarily results from destruction of uninfected erythrocytes. Parasitol. 1999;119:127-33.
39. Menendez C, Fleming AF, Alonso PL. Malaria-related anaemia. Parasitol Today. 2000;16:469-76.
40. Chotivanich K, Udomsangpetch R, Dondorp A, Williams T, Angus B, Simpson JA, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000;182:629-33.
41. Newton PN, Chotivanich K, Chierakul W, Ruagveerayuth R, Teerapong P, Silamut K, et al. A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes. Blood. 2001;98:450-7.
42. Angus BJ, Chotivanich K, Udomsangpetch White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;2037-2040.
43. Gbotosho GO, Okuboyejo TM, Happi CT, Sowunmi A. Fall in haematocrit per 1000 parasites cleared from peripheral blood: a simple method for estimating drug-related fall in haematocrit after treatment of malaria infections. Am J Ther. 2014;21:193-7.
44. Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, et al. Postartesunate delayed hemolyssis is a predictable event related to the lifesaving effect of artemisinins. Blood. 2014;124:167-75.
45. Arguin PM. Case definition: postartemisinin delayed hemolysis. Blood. 2014;124:157-8.
46. Rolling T, Agbenyega T, Issifou S, Adegnika J, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria-a double-center prospective study. J Infect Dis. 2014;209:1921-8.